USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
The company received one observation in the Form-483
The company received one observation in the Form-483
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The company received 1 (One) observation in the Form-483
Dilip Shanghvi to continue as the Executive Chairman of the Board
Zydus receives EIR for the API manufacturing facility at Ankleshwar
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Subscribe To Our Newsletter & Stay Updated